Research Analysts Set Expectations for VERA FY2025 Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Equities researchers at Cantor Fitzgerald dropped their FY2025 EPS estimates for shares of Vera Therapeutics in a note issued to investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will earn ($2.53) per share for the year, down from their prior forecast of ($2.22). The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share.

VERA has been the topic of a number of other reports. Guggenheim increased their price objective on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Wells Fargo & Company assumed coverage on Vera Therapeutics in a report on Thursday, November 21st. They issued an "overweight" rating and a $70.00 price target for the company. JPMorgan Chase & Co. reduced their price objective on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research note on Tuesday, March 4th. Wolfe Research initiated coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price objective on the stock. Finally, The Goldman Sachs Group initiated coverage on Vera Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $58.00 price target on the stock. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Vera Therapeutics currently has a consensus rating of "Buy" and an average price target of $64.67.

Remove Ads

Vera Therapeutics Price Performance

NASDAQ VERA traded down $1.02 on Thursday, reaching $27.80. The company had a trading volume of 724,724 shares, compared to its average volume of 889,733. Vera Therapeutics has a 12 month low of $25.99 and a 12 month high of $51.61. The firm's 50 day moving average price is $34.45 and its 200 day moving average price is $40.00. The stock has a market capitalization of $1.76 billion, a PE ratio of -10.65 and a beta of 1.17. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, beating analysts' consensus estimates of ($0.83) by $0.11.

Insider Activity at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of the company's stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $43.07, for a total transaction of $753,725.00. Following the completion of the sale, the chief executive officer now owns 85,942 shares of the company's stock, valued at $3,701,521.94. This represents a 16.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 52,500 shares of company stock valued at $2,305,625. Insiders own 21.70% of the company's stock.

Institutional Investors Weigh In On Vera Therapeutics

Several hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new stake in Vera Therapeutics during the 4th quarter worth approximately $56,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Vera Therapeutics by 30.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 80,106 shares of the company's stock worth $3,388,000 after buying an additional 18,532 shares during the period. Woodline Partners LP boosted its stake in shares of Vera Therapeutics by 20.1% during the 4th quarter. Woodline Partners LP now owns 1,202,466 shares of the company's stock worth $50,852,000 after buying an additional 201,573 shares during the last quarter. Vestal Point Capital LP acquired a new stake in shares of Vera Therapeutics in the fourth quarter valued at about $45,462,000. Finally, Thornburg Investment Management Inc. grew its stake in shares of Vera Therapeutics by 91.1% in the fourth quarter. Thornburg Investment Management Inc. now owns 59,004 shares of the company's stock valued at $2,495,000 after buying an additional 28,124 shares in the last quarter. Institutional investors own 99.21% of the company's stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.